2022年华东医药股份有限公司中报

Huadong Medicine Co., Ltd. Semi-Annual Report 2022 August 2022 Section I. Important Declaration, Contents and Definitions The Board of Directors, Board of Supervisors, directors, supervisors and senior management of Huadong Medicine Co., Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this half yearreport is authentic, accurate and complete and free of any false records, misleading statements or material omissions, and shall undertake individual and joint legal liabilities. Lv Liang, the Company’s legal representative and the officer in charge of accounting, and Qiu Renbo, head of accounting department (accounting supervisor) hereby declare and guarantee that the financial statements in this half year report are authentic, accurate and complete. All directors have attended the Board of Directors meeting to review this half year report. The future plans, development strategies and other forward-looking statements in this half year report shall not be considered as substantial commitment of the Company to investor. Investors and related parties should maintain sufficient risk awareness, and should understand the difference between plans, forecasts and promises. The risks the Company faces in operation including industry policy and market operation risk, new drug R&D risk, exchange rate fluctuation risk and goodwill impairment risk , etc. For details, refer to “X. Risks and Countermeasures” in“Section III. Discussion andAnalysis of the Management”. We thank all investors for paying attention to the Company’s operations, and we hope that you can be aware of investment risks. The company does not plan to distribute cash dividends, no bonus share will be issued; and no capital reserve will be converted to increase the share capital. Accordingto“StockListingRulesoftheShenzhenStockExchange”, if listed companies have both Chinese orother language version of public notice, they should ensure the content of both versions are the same. In the case of discrepancy, the original version in Chinese shall prevail. Contents Section I. Important Declaration, Contents and Definitions ...... 2 Contents...... 3 Definitions ...... 5 Section II. Company Profile and Key Financial Indicators ...... 7 Section III. Discussion andAnalysis of the Management......10 Section IV. Corporate Governance ......57 Section V. Environmental and Social Responsibility ......60 Section VI. Important Matters......72 Section VII. Share Change and Shareholders ......92 Section VIII. Preferred Shares ......100 Section IX. Information about Bonds ......101 Section X. Financial Report......102 Contents of Reference File I. Financial statements signed and stamped by the legal representative, the person in charge of accounting work and the head of accounting institution (accounting manager). II. The original of all Company’s documents publicly disclosed in the press designated by CSRC during the reporting period and the original of announcements. Definitions Term refers to Definition CSRC refers to China Securities Regulatory Commission SSE refers to Shenzhen Stock Exchange Huadong Medicine/the Company/our Company refers to Huadong Medicine Co., Ltd. CGE refers to China Grand Enterprises, Inc. Huadong Medicine Group refers to Hangzhou Huadong Medicine Group Co., Ltd. Zhongmei Huadong refers to Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Jiangdong Company refers to Hangzhou Zhongmei Huadong Pharmaceutical Jiangdong Co., Ltd. Jiuyang Bio refers to Jiangsu Jiuyang Biopharm Co., Ltd. Xi’an Bohua refers to Huadong Medicine (Xi’an) Bohua Pharmaceutical Co., Ltd. Jiuyuan Gene refers to Hangzhou Jiuyuan Gene Engineering Co., Ltd. Doer Biologics refers to Zhejiang Doer Biologics Co., Ltd. Huadong Ningbo Company refers to Huadong Ningbo Medicine Co., Ltd. Chongqing Peg-Bio refers to Chongqing Peg-Bio Biopharm Co., Ltd. Qyuns Therapeutics refers to Qyuns Therapeutics Co., Ltd. Nuoling Bio refers to Nuoling Biomedical technology (Beijing) Co., Ltd. Grand Chanrong refers to Shanghai Grand Industrial and Financial Investment Management Co., Ltd. Hangzhou Gaotou refers to Hangzhou Hi-Tech Venture Capital Management Co., Ltd. Grand Huachuang refers to Beijing Grand Huachuang Investment Co., Ltd. Hangzhou Heda refers to Hangzhou Heda Industrial Fund Investment Co., Ltd. Pharmaceutical Industry Fund/Fuguang refers to Hangzhou Fuguang Hongxin Equity Investment Partnership Hongxin (Limited Partnership) Meihua Hi-Tech refers to Anhui Meihua Hi-Tech Pharmaceutical Co., Ltd. Meiqi Health refers to Hubei Meiqi Health Technology Co., Ltd. Angel refers to Hubei Angel Bioengineering Group Co., Ltd. Takeda refers to Takeda Pharmaceuticals Company Ltd. Sinclair refers to Sinclair Pharma Limited vTv refers to vTv Therapeutics LLC R2 refers to R2 Technologies,Inc. MediBeacon refers to MediBeacon Inc. ImmunoGen refers to ImmunoGen, Inc. Provention Bio refers to Provention Bio, Inc. RAPT refers to RAPT Therapeutics,Inc. Kylane refers to Kylane Laboratoires SA High Tech refers to High Technology Products, S.L.U. Exscientia refers to Exscientia Ltd. Heidelberg Pharma refers to Heidelberg Pharma AG Kiniksa refers to Kiniksa Pharmaceuticals (UK), Ltd. KiOmed refers to KiOmed Pharma SA Daewon refers to Daewon Pharmaceutical Co., Ltd. AKSO refers to AKSO Biopharmaceutical, Inc. Ashvattha refers to Ashvattha Therapeutic, Inc. SCOHIA refers to SCOHIAPHARMA, Inc. EMAAesthetics refers to EMAAesthetics Limited Julphar refers to Gulf Pharmaceutical Industries PJSC(JULPHAR) GMP refers to Good Manufacturing Practice cGMP refers to Current Good Manufacture Practices GSP refers to Good Supply Practice BE refers to Bioequivalence CDE refers to Center for Drug Evaluation (of National Medical Products Administration) MAH refers to MarketingAuthorization Holder FDA refers to (U.S.) Food and DrugAdministration NMPA refers to National Medical Products Administration NHSA refers to National Healthcare SecurityAdministration NDA refers to New DrugApplication ANDA refers to Abbreviated New Drug Application (or Generic DrugApplication) ICH refers to International Councilfor Harmonisation (ofTechnical Requirements for Pharmaceuticals for Human Use) IND refers to Investigational New Drug PK/PD refers to pharmacokinetics/pharmacodynamics CMC refers to Chemistry, Manufacturing and Control CMO refers to Contract Manufacturing Organization CDMO refers to Contract Development and Manufacturing Organization QA refers to QualityAssurance (department) ADC refers to Antibody-Drug Conjugates EBD refers to Energy Based Device BD refers to Business Development EBITDA refers to Earnings Before Interest, Taxes, Depreciation and Amortization EHS refers to Environment, Health, Safety MRCT refers to International Multi-center Clinical Trial OTC refers to Over The Counter Prescription Drugs refers to Drugs that require medical prescriptions issued by physicians to be bought and used Catalogue of Drugs for Insurance（2021） refers to Catalogue of Drugs for Basic National Medical Insurance/Employment Injury Insurance/Birth Insurance（2021） Reporting Period refers to From January 1, 2022 to June 30, 2022 Section II. Company Profile and Key Financial Indicators I. Company information Stock name (abbreviation)